Abstract
The sepsis syndrome represents an improper immune response to pathogens and is associated with an unacceptably high rate of mortality. Although supportive care is of benefit to the septic patient, there are no viable therapeutics available that target the immune system suitable for the whole septic population. Recently, using a physiologically relevant murine mouse model, the cannabiniod 2 receptor has been shown to play a critical role in the host response to sepsis. Here, the structure, expression, signaling, and function of the CB2 receptor on leukocytes will be reviewed. Further, the effects mediated by the CB2 receptor during sepsis will be reviewed. Altogether, alterations in inflammation and the host response during sepsis by the CB2 receptor support its use as a possible therapeutic agent.
Keywords: Neutophils, macrophages, T cells, B cells, inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: The Cannabinoid 2 Receptor as a Potential Therapeutic Target for Sepsis
Volume: 10 Issue: 3
Author(s): Kevin Richard Kasten, Johannes Tschop, Matthias Hans Tschop and Charles Curtis Caldwell
Affiliation:
Keywords: Neutophils, macrophages, T cells, B cells, inflammation
Abstract: The sepsis syndrome represents an improper immune response to pathogens and is associated with an unacceptably high rate of mortality. Although supportive care is of benefit to the septic patient, there are no viable therapeutics available that target the immune system suitable for the whole septic population. Recently, using a physiologically relevant murine mouse model, the cannabiniod 2 receptor has been shown to play a critical role in the host response to sepsis. Here, the structure, expression, signaling, and function of the CB2 receptor on leukocytes will be reviewed. Further, the effects mediated by the CB2 receptor during sepsis will be reviewed. Altogether, alterations in inflammation and the host response during sepsis by the CB2 receptor support its use as a possible therapeutic agent.
Export Options
About this article
Cite this article as:
Richard Kasten Kevin, Tschop Johannes, Hans Tschop Matthias and Curtis Caldwell Charles, The Cannabinoid 2 Receptor as a Potential Therapeutic Target for Sepsis, Endocrine, Metabolic & Immune Disorders - Drug Targets 2010; 10 (3) . https://dx.doi.org/10.2174/187153010791936874
DOI https://dx.doi.org/10.2174/187153010791936874 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Circumscribing the Conformational Peptide Epitope Landscape
Current Pharmaceutical Design Chronic Inflammatory Diseases: Progress and Prospect with Herbal Medicine
Current Pharmaceutical Design Kv1.3 Lymphocyte Potassium Channel Inhibition as a Potential Novel Therapeutic Target in Acute Ischemic Stroke
CNS & Neurological Disorders - Drug Targets Lactose and Casein Cause Changes on Biomarkers of Oxidative Damage and Dysbiosis in an Experimental Model of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Withdrawn: Effects of Tofacitinib on Tfr/Tfh Balance and Expression of CXCL13 and TGF-β1 in Experimental Autoimmune Encephalomyelitis Rats
CNS & Neurological Disorders - Drug Targets Discovery of GPCR Ligands by Molecular Docking Screening: Novel Opportunities Provided by Crystal Structures
Current Topics in Medicinal Chemistry Inhibitors of the Immunoproteasome: Current Status and Future Directions
Current Pharmaceutical Design Pharmacogenomics and the Treatment of Sporadic Alzheimers Disease:A Decade of Progress
Current Pharmacogenomics and Personalized Medicine Central Nervous System Involvement in Pediatric Rheumatic Diseases: Current Concepts in Treatment
Current Pharmaceutical Design Negative Regulation of TCR Signaling in Immunological Tolerance: Taming Good and Evil
Current Immunology Reviews (Discontinued) Synthetic Glycolipid Ligands for Human iNKT Cells as Potential Therapeutic Agents for Immunotherapy
Current Medicinal Chemistry Immune Responses to Gene Product of Inducible Promoters
Current Gene Therapy Targeting the Chemokine Receptor CXCR3 and Its Ligand CXCL10 in the Central Nervous System: Potential Therapy for Inflammatory Demyelinating Disease?
Current Neurovascular Research Polyphenols as Potential Therapeutics for Pain and Inflammation in Spinal Cord Injury
Current Molecular Pharmacology The Blood-Central Nervous System Barriers Actively Control Immune Cell Entry into the Central Nervous System
Current Pharmaceutical Design Astrocyte`s RAGE: More Than Just a Question of Mood
Central Nervous System Agents in Medicinal Chemistry Mast Cells and Basophils: Trojan Horses of Conventional Lin- Stem/Progenitor Cell Isolates
Current Pharmaceutical Design The Expression, Function and Targeting of Haem Oxygenase-1 in Cancer
Current Cancer Drug Targets Erythropoietin in Heart Failure and Other Cardiovascular Diseases: Hematopoietic and Pleiotropic Effects
Current Drug Targets - Cardiovascular & Hematological Disorders Artery of Percheron Infarction: A Characteristic Pattern of Ischemia and Variable Clinical Presentation: A Literature Review
Current Medical Imaging